This company has been acquired
Resumen de acción AERI
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Competidores de Aerie Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.25 |
| 52 Week High | US$15.37 |
| 52 Week Low | US$4.81 |
| Beta | -0.062 |
| 1 Month Change | 0.26% |
| 3 Month Change | 0.59% |
| 1 Year Change | 57.22% |
| 3 Year Change | -17.66% |
| 5 Year Change | -74.98% |
| Change since IPO | 43.73% |
Noticias y actualizaciones recientes
Recent updates
Alcon to acquire Aerie Pharmaceuticals at ~$770M, enhancing its ophthalmic pharmaceutical portfolio
Aug 23Aerie Pharmaceuticals grants 16.9K stock options
Aug 15Aerie Pharma rises 14% after Q2 result beat on higher glaucoma franchise sales
Aug 05Aerie Pharma completes enrollment in first Phase 3 trial of netarsudil in Japan
Jun 17Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
Feb 27
Who Has Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares?
Jan 28Aerie Pharmaceuticals receives European approval for Roclanda
Jan 11Aerie Pharmaceuticals (NASDAQ:AERI) Share Prices Have Dropped 76% In The Last Three Years
Dec 24Is Aerie Pharmaceuticals (NASDAQ:AERI) A Risky Investment?
Nov 28
European advisory group backs Aerie Pharma's Roclanda
Nov 13Rentabilidad de los accionistas
| AERI | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 0.1% | -1.4% | -3.2% |
| 1Y | 57.2% | 9.7% | 19.3% |
Rentabilidad vs. Industria: AERI exceeded the US Pharmaceuticals industry which returned 7.7% over the past year.
Rentabilidad vs. Mercado: AERI exceeded the US Market which returned -21.7% over the past year.
Volatilidad de los precios
| AERI volatility | |
|---|---|
| AERI Average Weekly Movement | 10.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: AERI's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: AERI's weekly volatility (10%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2005 | 376 | Raj Kannan | www.aeriepharma.com |
Resumen de fundamentos de Aerie Pharmaceuticals, Inc.
| Estadísticas fundamentales de AERI | |
|---|---|
| Capitalización bursátil | US$753.62m |
| Beneficios(TTM) | -US$36.55m |
| Ingresos (TTM) | US$213.94m |
3.5x
Ratio precio-ventas (PS)-20.6x
Ratio precio-beneficio (PE)¿Está AERI sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AERI | |
|---|---|
| Ingresos | US$213.94m |
| Coste de los ingresos | US$23.52m |
| Beneficio bruto | US$190.42m |
| Otros gastos | US$226.98m |
| Beneficios | -US$36.55m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.74 |
| Margen bruto | 89.01% |
| Margen de beneficio neto | -17.09% |
| Ratio deuda/patrimonio | -190.6% |
¿Cómo se ha desempeñado AERI a largo plazo?
Ver rendimiento histórico y comparativa